Skip to main content

Sarepta stock hit by renewed uncertainty about gene therapy treatment for rare disease

A report said the FDA was leaning toward rejecting a treatment for Duchenne muscular dystrophy that the company seemed to view as a sure thing.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.